Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 13/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586208 | 0.85 | MEN1 (0.43) | RYR2HTR1ASLC6A4 | |
| SCHEMBL3587135 | 0.84 | PIK3CG (0.52) | RYR2HTR1ASLC6A4PIK3CG | |
| SCHEMBL3574540 | 0.84 | MTNR1A (0.44) | RYR2HTR1ASLC6A4 | |
| SCHEMBL3580606 | 0.82 | PIK3CG (0.42) | RYR2HTR1ASLC6A4PIK3CG | |
| SCHEMBL3580603 | 0.82 | ALDH1A1 (0.41) | RYR2HTR1ASLC6A4 | |
| SCHEMBL3575811 | 0.81 | PIK3CG (0.47) | RYR2HTR1ASLC6A4PIK3CG | |
| SCHEMBL3573588 | 0.81 | RYR2 (0.43) | RYR2HTR1ASLC6A4PIK3CG | |
| SCHEMBL3582590 | 0.81 | PIK3CG (0.43) | RYR2HTR1ASLC6A4PIK3CG | |
| SCHEMBL28076607 | 0.79 | HTR1A (0.58) | HTR1ASLC6A4 | |
| SCHEMBL3582211 | 0.78 | EPHX2 (0.55) | RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | RYR2 3197/4885HTR1A 1658/4885SLC6A4 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.